Clinical Convergence^® Unresectable HCC: An Emerging Era of Combination Therapy

Program Overview

In this web-based CME activity, experts discuss recent developments in the treatment of hepatocellular carcinoma (HCC). Do not miss this opportunity to learn more about new and emerging combination strategies and receive practical guidance on their integration into clinical practice.

You will hear first-hand from an experienced patient with HCC who will share his personal journey and offer a novel perspective for healthcare professionals.

Credit Expired

Target Audience

This activity is intended for hepatology, hematology/oncology, and other clinicians including physicians, NPs, and PAs who diagnose and manage patients with hepatocellular carcinoma (HCC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Develop treatment plans for patients with advanced hepatocellular carcinoma (HCC) that integrate checkpoint inhibitors and targeted synthetic agents based on their efficacy and safety data
Develop individualized treatment plans for patients with advanced HCC across multiple lines of therapy
Analyze the safety and efficacy of new and emerging combination regimens for HCC

Activity Faculty

Richard S. Finn, MD

Professor, Department of Medicine
Division of Hematology/Oncology
UCLA David Geffen School of Medicine
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center
University of California
Los Angeles, CA

Amit Singal, MD, MS  

David Bruton Jr. Professor, Clinical Cancer Research
Professor, Medicine
Chief and Medical Director, Liver Tumor Program
UT Southwestern Medical Center
Dallas, TX

Mark Yarchoan, MD

Assistant Professor, Division of GI Malignancies
Medical Oncology Director, Liver Cancer Multidisciplinary Clinic
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, MD

Featured RMEI CE Activities – Earn CE Credit(s)

Clinical Convergence^® Unresectable HCC: An Emerging Era of Combination Therapy

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Richard S. Finn, MD

Amit Singal, MD, MS

Mark Yarchoan, MD

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Subscribe

Clinical Convergence® Unresectable HCC: An Emerging Era of Combination Therapy

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Richard S. Finn, MD

Amit Singal, MD, MS

Mark Yarchoan, MD

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Subscribe

Clinical Convergence^® Unresectable HCC: An Emerging Era of Combination Therapy

Amit Singal, MD, MS  